Abingworth is a transatlantic life sciences investment firm specializing in early and late-stage investments in biotechnology and healthcare companies across the United States and Europe. Founded in 1987, Abingworth has invested in over 100 startups and has offices in London, Boston, and San Francisco.

Investment Focus:

Abingworth invests across three strategic areas:

Seed and Early Stage: Supporting innovative startups developing groundbreaking technologies.

Development Stage: Investing in companies advancing their products through clinical trials and regulatory approvals.

Clinical Co-Development: Collaborating with pharmaceutical and biotechnology partners to co-develop clinical programs.